KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBIT (2016 - 2025)

Historic EBIT for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $6.4 million.

  • Pacira BioSciences' EBIT rose 10455.97% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 16402.24%. This contributed to the annual value of -$73.4 million for FY2024, which is 18368.52% down from last year.
  • Per Pacira BioSciences' latest filing, its EBIT stood at $6.4 million for Q3 2025, which was up 10455.97% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' EBIT registered a high of $39.9 million during Q2 2023, and its lowest value of -$139.5 million during Q3 2024.
  • Over the past 5 years, Pacira BioSciences' median EBIT value was $17.7 million (recorded in 2023), while the average stood at $9.5 million.
  • In the last 5 years, Pacira BioSciences' EBIT surged by 58751.92% in 2021 and then tumbled by 88735.4% in 2024.
  • Quarter analysis of 5 years shows Pacira BioSciences' EBIT stood at $4.2 million in 2021, then crashed by 334.93% to -$9.9 million in 2022, then surged by 435.27% to $33.2 million in 2023, then decreased by 25.52% to $24.7 million in 2024, then plummeted by 74.25% to $6.4 million in 2025.
  • Its EBIT stands at $6.4 million for Q3 2025, versus $8.5 million for Q2 2025 and $2.0 million for Q1 2025.